Do analysts rate CELU or HURA?

TuHURA Biosciences has a consensus target price of $9.00, indicating a potential upside of 354.55%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Celularity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TuHURA Biosciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is CELU or HURA more profitable?

Celularity's return on equity of 0.00% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Celularity N/A N/A N/A TuHURA Biosciences N/A -156.47% -106.98%

Do analysts prefer IMDX or CELU?

Oncocyte currently has a consensus price target of $10.50, suggesting a potential upside of 202.59%. Given Oncocyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Oncocyte is more favorable than Celularity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncocyte 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IMDX or CELU more profitable?

Celularity has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%. Company Net Margins Return on Equity Return on Assets Oncocyte -2,955.63% N/A -107.52% Celularity N/A N/A N/A

Does the media favor IMDX or CELU?

In the previous week, Celularity had 5 more articles in the media than Oncocyte. MarketBeat recorded 11 mentions for Celularity and 6 mentions for Oncocyte. Celularity's average media sentiment score of 0.41 beat Oncocyte's score of 0.26 indicating that Celularity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncocyte 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Celularity 0 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is INO or CELU more profitable?

Celularity's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Inovio Pharmaceuticals N/A -669.94% -73.97% Celularity N/A N/A N/A

Does the media prefer INO or CELU?

In the previous week, Celularity had 10 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 11 mentions for Celularity and 1 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 1.10 beat Celularity's score of 0.41 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inovio Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celularity 0 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CELU or OKUR?

OnKure Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 588.98%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Celularity. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celularity 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OnKure Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is CELU or OKUR more profitable?

Celularity's return on equity of 0.00% beat OnKure Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Celularity N/A N/A N/A OnKure Therapeutics N/A -49.01% -45.77%

Does the media refer more to CELU or OKUR?

In the previous week, Celularity had 9 more articles in the media than OnKure Therapeutics. MarketBeat recorded 11 mentions for Celularity and 2 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.45 beat Celularity's score of 0.41 indicating that OnKure Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celularity 0 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Celularity (CELU) Competitors

$1.38 +0.03 (+2.22%)

Closing price 04:00 PM Eastern

Extended Trading

$1.36 -0.02 (-1.81%)

As of 07:30 PM Eastern

Compare

CELU vs. HURA, IMDX, INO, OKUR, and COYA

Should you buy Celularity stock or one of its competitors? Celularity's main competitors and comparable companies include TuHURA Biosciences (HURA), Oncocyte (IMDX), Inovio Pharmaceuticals (INO), OnKure Therapeutics (OKUR), and Coya Therapeutics (COYA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Celularity compare to TuHURA Biosciences?

Celularity (NASDAQ:CELU) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Celularity has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.21, meaning that its share price is 121% less volatile than the broader market.

TuHURA Biosciences has lower revenue, but higher earnings than Celularity. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.50	-$91.72M	-$3.33	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.54	N/A

19.0% of Celularity shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Celularity's return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	N/A	N/A	N/A
TuHURA Biosciences	N/A	-156.47%	-106.98%

TuHURA Biosciences has a consensus target price of $9.00, indicating a potential upside of 354.55%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Celularity had 11 more articles in the media than TuHURA Biosciences. MarketBeat recorded 11 mentions for Celularity and 0 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 1.71 beat Celularity's score of 0.41 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Celularity	Neutral
TuHURA Biosciences	Very Positive

Summary

Celularity beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks.

How does Celularity compare to Oncocyte?

Oncocyte (NASDAQ:IMDX) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Celularity has a net margin of 0.00% compared to Oncocyte's net margin of -2,955.63%.

Company	Net Margins	Return on Equity	Return on Assets
Oncocyte	-2,955.63%	N/A	-107.52%
Celularity	N/A	N/A	N/A

Oncocyte currently has a consensus price target of $10.50, suggesting a potential upside of 202.59%. Given Oncocyte's stronger consensus rating and higher probable upside, equities analysts plainly believe Oncocyte is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncocyte	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Celularity had 5 more articles in the media than Oncocyte. MarketBeat recorded 11 mentions for Celularity and 6 mentions for Oncocyte. Celularity's average media sentiment score of 0.41 beat Oncocyte's score of 0.26 indicating that Celularity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oncocyte	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celularity	0 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oncocyte has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market. Comparatively, Celularity has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Oncocyte has higher earnings, but lower revenue than Celularity. Oncocyte is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncocyte	$4.05M	28.03	-$50.22M	-$1.49	N/A
Celularity	$26.55M	1.50	-$91.72M	-$3.33	N/A

55.4% of Oncocyte shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 2.2% of Oncocyte shares are held by company insiders. Comparatively, 17.3% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Oncocyte beats Celularity on 8 of the 14 factors compared between the two stocks.

How does Celularity compare to Inovio Pharmaceuticals?

Inovio Pharmaceuticals (NASDAQ:INO) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Inovio Pharmaceuticals has higher earnings, but lower revenue than Celularity. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$60K	2,085.23	-$84.95M	-$0.91	N/A
Celularity	$26.55M	1.50	-$91.72M	-$3.33	N/A

Inovio Pharmaceuticals has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Celularity has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 1.7% of Inovio Pharmaceuticals shares are held by insiders. Comparatively, 17.3% of Celularity shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Celularity had 10 more articles in the media than Inovio Pharmaceuticals. MarketBeat recorded 11 mentions for Celularity and 1 mentions for Inovio Pharmaceuticals. Inovio Pharmaceuticals' average media sentiment score of 1.10 beat Celularity's score of 0.41 indicating that Inovio Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celularity	0 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inovio Pharmaceuticals currently has a consensus price target of $3.17, suggesting a potential upside of 161.71%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Inovio Pharmaceuticals is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Celularity's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%
Celularity	N/A	N/A	N/A

Summary

Inovio Pharmaceuticals beats Celularity on 10 of the 16 factors compared between the two stocks.

How does Celularity compare to OnKure Therapeutics?

Celularity (NASDAQ:CELU) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

OnKure Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 588.98%. Given OnKure Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe OnKure Therapeutics is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OnKure Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

OnKure Therapeutics has lower revenue, but higher earnings than Celularity. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	1.50	-$91.72M	-$3.33	N/A
OnKure Therapeutics	N/A	N/A	-$59.52M	-$3.50	N/A

In the previous week, Celularity had 9 more articles in the media than OnKure Therapeutics. MarketBeat recorded 11 mentions for Celularity and 2 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 0.45 beat Celularity's score of 0.41 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celularity	0 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OnKure Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celularity's return on equity of 0.00% beat OnKure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	N/A	N/A	N/A
OnKure Therapeutics	N/A	-49.01%	-45.77%

Celularity has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, OnKure Therapeutics has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

19.0% of Celularity shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 2.2% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Celularity beats OnKure Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Celularity compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Coya Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, Celularity has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

In the previous week, Celularity had 11 more articles in the media than Coya Therapeutics. MarketBeat recorded 11 mentions for Celularity and 0 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 1.82 beat Celularity's score of 0.41 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coya Therapeutics	Very Positive
Celularity	Neutral

Coya Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 224.17%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Coya Therapeutics is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Celularity	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Coya Therapeutics has higher earnings, but lower revenue than Celularity. Coya Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	13.96	-$21.23M	-$1.07	N/A
Celularity	$26.55M	1.50	-$91.72M	-$3.33	N/A

Celularity has a net margin of 0.00% compared to Coya Therapeutics' net margin of -270.22%. Celularity's return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
Celularity	N/A	N/A	N/A

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by company insiders. Comparatively, 17.3% of Celularity shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Coya Therapeutics and Celularity tied by winning 8 of the 16 factors compared between the two stocks.

Get Celularity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELU vs. The Competition

Export

Metric	Celularity	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$39.08M	$3.94B	$7.23B	$13.08B
Dividend Yield	N/A	3.64%	2.53%	15.87%
P/E Ratio	-0.41	7.98	213.54	21.25
Price / Sales	1.50	1,293.92	607.24	91.04
Price / Cash	N/A	121.76	77.38	51.29
Price / Book	-1.05	15.66	10.51	6.26
Net Income	-$91.72M	-$22.67M	$3.50B	$360.95M
7 Day Performance	4.55%	-3.44%	-2.48%	-1.89%
1 Month Performance	-26.60%	-9.36%	-5.65%	-3.43%
1 Year Performance	-32.35%	22.41%	9.54%	2.60%

Celularity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELU Celularity	0.703 of 5 stars	$1.38 +2.2%	N/A	-34.8%	$39.08M	$26.55M	N/A	115	News Coverage Earnings Report Short Interest Decrease
HURA TuHURA Biosciences	1.749 of 5 stars	$2.13 -2.3%	$9.00 +322.5%	-15.3%	$135.75M	N/A	N/A	22	Positive News
IMDX Oncocyte	1.8512 of 5 stars	$4.14 +3.2%	$10.50 +153.6%	N/A	$135.46M	$4.05M	N/A	58	News Coverage
INO Inovio Pharmaceuticals	3.0492 of 5 stars	$1.29 +4.0%	$3.17 +145.5%	-47.9%	$133.39M	$60K	N/A	112
OKUR OnKure Therapeutics	2.9793 of 5 stars	$3.10 +1.3%	$17.50 +464.5%	-1.1%	$125.24M	N/A	N/A	45

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELU) was last updated on 10/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celularity (CELU) Competitors

CELU vs. HURA, IMDX, INO, OKUR, and COYA

How does Celularity compare to TuHURA Biosciences?

Summary

How does Celularity compare to Oncocyte?

Summary

How does Celularity compare to Inovio Pharmaceuticals?

Summary

How does Celularity compare to OnKure Therapeutics?

Summary

How does Celularity compare to Coya Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celularity (CELU) Competitors

CELU vs. HURA, IMDX, INO, OKUR, and COYA

How does Celularity compare to TuHURA Biosciences?

Which has more volatility and risk, CELU or HURA?

Which has stronger valuation and earnings, CELU or HURA?

Do insiders and institutionals believe in CELU or HURA?

Is CELU or HURA more profitable?

Do analysts rate CELU or HURA?

Does the media refer more to CELU or HURA?

Summary

How does Celularity compare to Oncocyte?

Is IMDX or CELU more profitable?

Do analysts prefer IMDX or CELU?

Does the media favor IMDX or CELU?

Which has more volatility and risk, IMDX or CELU?

Which has better earnings & valuation, IMDX or CELU?

Do insiders & institutionals have more ownership in IMDX or CELU?

Summary

How does Celularity compare to Inovio Pharmaceuticals?

Which has better valuation and earnings, INO or CELU?

Which has more risk and volatility, INO or CELU?

Do institutionals & insiders hold more shares of INO or CELU?

Does the media prefer INO or CELU?

Do analysts prefer INO or CELU?

Is INO or CELU more profitable?

Summary

How does Celularity compare to OnKure Therapeutics?

Do analysts recommend CELU or OKUR?

Which has stronger earnings and valuation, CELU or OKUR?

Does the media refer more to CELU or OKUR?

Is CELU or OKUR more profitable?

Which has more volatility and risk, CELU or OKUR?

Do insiders & institutionals have more ownership in CELU or OKUR?

Summary

How does Celularity compare to Coya Therapeutics?

Which has more volatility and risk, COYA or CELU?

Does the media prefer COYA or CELU?

Do analysts prefer COYA or CELU?

Which has higher earnings and valuation, COYA or CELU?

Is COYA or CELU more profitable?

Do insiders & institutionals believe in COYA or CELU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools